Granulomatosis with Polyangiitis Drug Market - Global Outlook and Forecast 2021-2027

Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Granulomatosis with Polyangiitis Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Granulomatosis with Polyangiitis Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Granulomatosis with Polyangiitis Drug Overall Market Size
2.1 Global Granulomatosis with Polyangiitis Drug Market Size: 2021 VS 2027
2.2 Global Granulomatosis with Polyangiitis Drug Revenue, Prospects & Forecasts: 2016-2027
2.3 Global Granulomatosis with Polyangiitis Drug Sales (Consumption): 2016-2027
3 Company Landscape
3.1 Top Granulomatosis with Polyangiitis Drug Players in Global Market
3.2 Top Global Granulomatosis with Polyangiitis Drug Companies Ranked by Revenue
3.3 Global Granulomatosis with Polyangiitis Drug Revenue by Companies
3.4 Global Granulomatosis with Polyangiitis Drug Sales by Companies
3.5 Global Granulomatosis with Polyangiitis Drug Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Granulomatosis with Polyangiitis Drug Companies in Global Market, by Revenue in 2020
3.7 Global Manufacturers Granulomatosis with Polyangiitis Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Granulomatosis with Polyangiitis Drug Players in Global Market
3.8.1 List of Global Tier 1 Granulomatosis with Polyangiitis Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Granulomatosis with Polyangiitis Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Granulomatosis with Polyangiitis Drug Market Size Markets, 2021 & 2027
4.1.2 Benralizumab
4.1.3 Avacopan
4.1.4 Rituximab Biosimilar
4.1.5 Others
4.2 By Type - Global Granulomatosis with Polyangiitis Drug Revenue & Forecasts
4.2.1 By Type - Global Granulomatosis with Polyangiitis Drug Revenue, 2016-2021
4.2.2 By Type - Global Granulomatosis with Polyangiitis Drug Revenue, 2022-2027
4.2.3 By Type - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2016-2027
4.3 By Type - Global Granulomatosis with Polyangiitis Drug Sales & Forecasts
4.3.1 By Type - Global Granulomatosis with Polyangiitis Drug Sales, 2016-2021
4.3.2 By Type - Global Granulomatosis with Polyangiitis Drug Sales, 2022-2027
4.3.3 By Type - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2016-2027
4.4 By Type - Global Granulomatosis with Polyangiitis Drug Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Granulomatosis with Polyangiitis Drug Market Size, 2021 & 2027
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application - Global Granulomatosis with Polyangiitis Drug Revenue & Forecasts
5.2.1 By Application - Global Granulomatosis with Polyangiitis Drug Revenue, 2016-2021
5.2.2 By Application - Global Granulomatosis with Polyangiitis Drug Revenue, 2022-2027
5.2.3 By Application - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2016-2027
5.3 By Application - Global Granulomatosis with Polyangiitis Drug Sales & Forecasts
5.3.1 By Application - Global Granulomatosis with Polyangiitis Drug Sales, 2016-2021
5.3.2 By Application - Global Granulomatosis with Polyangiitis Drug Sales, 2022-2027
5.3.3 By Application - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2016-2027
5.4 By Application - Global Granulomatosis with Polyangiitis Drug Price (Manufacturers Selling Prices), 2016-2027
6 Sights by Region
6.1 By Region - Global Granulomatosis with Polyangiitis Drug Market Size, 2021 & 2027
6.2 By Region - Global Granulomatosis with Polyangiitis Drug Revenue & Forecasts
6.2.1 By Region - Global Granulomatosis with Polyangiitis Drug Revenue, 2016-2021
6.2.2 By Region - Global Granulomatosis with Polyangiitis Drug Revenue, 2022-2027
6.2.3 By Region - Global Granulomatosis with Polyangiitis Drug Revenue Market Share, 2016-2027
6.3 By Region - Global Granulomatosis with Polyangiitis Drug Sales & Forecasts
6.3.1 By Region - Global Granulomatosis with Polyangiitis Drug Sales, 2016-2021
6.3.2 By Region - Global Granulomatosis with Polyangiitis Drug Sales, 2022-2027
6.3.3 By Region - Global Granulomatosis with Polyangiitis Drug Sales Market Share, 2016-2027
6.4 North America
6.4.1 By Country - North America Granulomatosis with Polyangiitis Drug Revenue, 2016-2027
6.4.2 By Country - North America Granulomatosis with Polyangiitis Drug Sales, 2016-2027
6.4.3 US Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.4.4 Canada Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.4.5 Mexico Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.5 Europe
6.5.1 By Country - Europe Granulomatosis with Polyangiitis Drug Revenue, 2016-2027
6.5.2 By Country - Europe Granulomatosis with Polyangiitis Drug Sales, 2016-2027
6.5.3 Germany Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.5.4 France Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.5.5 U.K. Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.5.6 Italy Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.5.7 Russia Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.5.8 Nordic Countries Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.5.9 Benelux Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.6 Asia
6.6.1 By Region - Asia Granulomatosis with Polyangiitis Drug Revenue, 2016-2027
6.6.2 By Region - Asia Granulomatosis with Polyangiitis Drug Sales, 2016-2027
6.6.3 China Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.6.4 Japan Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.6.5 South Korea Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.6.6 Southeast Asia Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.6.7 India Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.7 South America
6.7.1 By Country - South America Granulomatosis with Polyangiitis Drug Revenue, 2016-2027
6.7.2 By Country - South America Granulomatosis with Polyangiitis Drug Sales, 2016-2027
6.7.3 Brazil Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.7.4 Argentina Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Revenue, 2016-2027
6.8.2 By Country - Middle East & Africa Granulomatosis with Polyangiitis Drug Sales, 2016-2027
6.8.3 Turkey Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.8.4 Israel Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.8.5 Saudi Arabia Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
6.8.6 UAE Granulomatosis with Polyangiitis Drug Market Size, 2016-2027
7 Manufacturers & Brands Profiles
7.1 Bionovis SA
7.1.1 Bionovis SA Corporate Summary
7.1.2 Bionovis SA Business Overview
7.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Major Product Offerings
7.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.1.5 Bionovis SA Key News
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Corporate Summary
7.2.2 Bristol-Myers Squibb Company Business Overview
7.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Major Product Offerings
7.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.2.5 Bristol-Myers Squibb Company Key News
7.3 ChemoCentryx Inc
7.3.1 ChemoCentryx Inc Corporate Summary
7.3.2 ChemoCentryx Inc Business Overview
7.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Major Product Offerings
7.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.3.5 ChemoCentryx Inc Key News
7.4 Coherus BioSciences Inc
7.4.1 Coherus BioSciences Inc Corporate Summary
7.4.2 Coherus BioSciences Inc Business Overview
7.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Major Product Offerings
7.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.4.5 Coherus BioSciences Inc Key News
7.5 Genor BioPharma Co Ltd
7.5.1 Genor BioPharma Co Ltd Corporate Summary
7.5.2 Genor BioPharma Co Ltd Business Overview
7.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Major Product Offerings
7.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.5.5 Genor BioPharma Co Ltd Key News
7.6 GlaxoSmithKline Plc
7.6.1 GlaxoSmithKline Plc Corporate Summary
7.6.2 GlaxoSmithKline Plc Business Overview
7.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Major Product Offerings
7.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.6.5 GlaxoSmithKline Plc Key News
7.7 Iltoo Pharma
7.7.1 Iltoo Pharma Corporate Summary
7.7.2 Iltoo Pharma Business Overview
7.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Major Product Offerings
7.4.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.7.5 Iltoo Pharma Key News
7.8 Panacea Biotec Ltd
7.8.1 Panacea Biotec Ltd Corporate Summary
7.8.2 Panacea Biotec Ltd Business Overview
7.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Major Product Offerings
7.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.8.5 Panacea Biotec Ltd Key News
7.9 Sandoz International GmbH
7.9.1 Sandoz International GmbH Corporate Summary
7.9.2 Sandoz International GmbH Business Overview
7.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Major Product Offerings
7.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.9.5 Sandoz International GmbH Key News
7.10 The International Biotechnology Center (IBC) Generium
7.10.1 The International Biotechnology Center (IBC) Generium Corporate Summary
7.10.2 The International Biotechnology Center (IBC) Generium Business Overview
7.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Major Product Offerings
7.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales and Revenue in Global (2016-2021)
7.10.5 The International Biotechnology Center (IBC) Generium Key News
8 Global Granulomatosis with Polyangiitis Drug Production Capacity, Analysis
8.1 Global Granulomatosis with Polyangiitis Drug Production Capacity, 2016-2027
8.2 Granulomatosis with Polyangiitis Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Granulomatosis with Polyangiitis Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Granulomatosis with Polyangiitis Drug Supply Chain Analysis
10.1 Granulomatosis with Polyangiitis Drug Industry Value Chain
10.2 Granulomatosis with Polyangiitis Drug Upstream Market
10.3 Granulomatosis with Polyangiitis Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Granulomatosis with Polyangiitis Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer


List of Tables
Table 1. Key Players of Granulomatosis with Polyangiitis Drug in Global Market
Table 2. Top Granulomatosis with Polyangiitis Drug Players in Global Market, Ranking by Revenue (2019)
Table 3. Global Granulomatosis with Polyangiitis Drug Revenue by Companies, (US$, Mn), 2016-2021
Table 4. Global Granulomatosis with Polyangiitis Drug Revenue Share by Companies, 2016-2021
Table 5. Global Granulomatosis with Polyangiitis Drug Sales by Companies, (K Pcs), 2016-2021
Table 6. Global Granulomatosis with Polyangiitis Drug Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Granulomatosis with Polyangiitis Drug Price (2016-2021) & (USD/Pcs)
Table 8. Global Manufacturers Granulomatosis with Polyangiitis Drug Product Type
Table 9. List of Global Tier 1 Granulomatosis with Polyangiitis Drug Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Granulomatosis with Polyangiitis Drug Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type

Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx Inc
Coherus BioSciences Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Iltoo Pharma
Panacea Biotec Ltd
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium